Substantial studies demonstrated that STC1 overexpression drives tumor aggressiveness through NOTCH1/SOX2 and TGF‐β pathways in GBM [19, 20], while also contributing to angiogenesis [21] and temozolomide (TMZ) resistance via MGMT regulation [22]. This evidence concerns the gene STC1 and neoplasm.